Skip to main content
NewslettersWatchlist

Sanofi-Aventis S.A. ADR(SNY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low48.17
Day High49.47
Open:48.84
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Sanofi (SNY) Q1 2024 Earnings Call Transcript
Barchart
Beyond the GRANOLAS: JPMorgan Picks 3 Top Stocks to Bet on Europe
Motley Fool
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Motley Fool
Sanofi (SNY) Q4 2023 Earnings Call Transcript
Motley Fool
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
Motley Fool
3 Stocks to Buy Before 2024 That Can Set You Up For Life
Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
MarketBeat
Informatica soars on its AI-powered data management cloud growth
MarketBeat
MarketBeat Week in Review – 11/6 - 11/10
AllPennyStocks.com
Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time
MarketBeat
Pfizer and Sanofi shares fall, which one to scoop up?
Motley Fool
This Stock Just Dropped By 15%: Is It a Buy?
Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
MarketBeat
Investor patience tested as pharmaceutical stocks take a tumble
Baystreet
This High-Yielding ETF Gives Investors Great Exposure to European Stocks
Motley Fool
Sanofi (SNY) Q3 2023 Earnings Call Transcript
Motley Fool
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
Motley Fool
2 Surefire Stocks That Could Make You Richer
PR Newswire
Stagwell's (STGW) The Harris Poll Unveils First-of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers
Motley Fool
Why Shares of Kymera Therapeutics Jumped on Tuesday
Motley Fool
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
Motley Fool
This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now
PR Newswire
Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
Motley Fool
Could This Medicine Be the Next Winner for Novartis?
Motley Fool
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
Motley Fool
2 Biotech Stocks That Could Make You Richer
Motley Fool
2 Top Biotech Stocks to Buy Right Now
Motley Fool
Why Shares of MacroGenics Are Jumping Thursday
MarketBeat
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Motley Fool
The Top Healthcare Stocks to Buy With $100
Motley Fool
Sanofi (SNY) Q2 2023 Earnings Call Transcript
MarketBeat
Exscientia is the Sniper of the AI Drug Discovery Industry

Profile

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.